Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00561431 · ClinicalTrials.gov registry record · Phase 3
High Dose CVVHDF Compared to Standard Dose CVVHDF
A Phase 3 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
NCT00561431 is a Phase 3 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 200 participants.
The verdict
NCT00561431, a Phase 3 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
Study Summary
In the last three decades, the mortality associated with acute renal failure (ARF) in the ICU has remained unchanged at greater than 50%, despite improvements in dialysis technology. The primary objective is to determine whether Continuous Veno-Venous Hemodiafiltration (CVVHDF) using an ultrafiltration rate of 35 ml/hr/kg (high dose) leads to a greater reduction in all-cause ICU mortality compared to standard CVVHDF using an ultrafiltration rate of 20 ml/hr/kg.
Interventions
- DEVICE Standard dose of dialysis
- DEVICE High dose of dialysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2003-07 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00561431
The ClinicalTrials.gov registry entry for NCT00561431 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard dose of dialysis is the first listed.
NCT00561431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00561431 about?
NCT00561431 is a clinical study titled "High Dose CVVHDF Compared to Standard Dose CVVHDF". In the last three decades, the mortality associated with acute renal failure (ARF) in the ICU has remained unchanged at greater than 50%, despite improvements in dialysis technology. The primary objective is to determine whether Continuous Veno-Venous Hemodiafiltration (CVVHDF) using an ultrafiltra...
What is the current status of trial NCT00561431?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2003-07. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00561431?
The interventions under investigation include: Standard dose of dialysis (DEVICE), High dose of dialysis (DEVICE).
Who is sponsoring clinical trial NCT00561431?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.